The Ministry of Health and Welfare announced Wednesday that it would add Pfizer’s targeted therapy for kidney cancer Inlyta (ingredient: axitinib) to the list of reimbursed drugs starting in July.

The ministry listed Inlyta at 10,000 won ($9) for a 1 mg dose and 36,092 won for a 5 ml dose beginning next month. The drug was approved in August 2012 to treat patients with progressive renal cell carcinoma who have failed one type of systemic therapy.

Shire’s hemophilia treatment Adynovate was also added to the list at 675 won per bottle. The therapy was approved in February.

Adynovate, which is made from the same ingredient as hemophilia A therapy Advate, is a long-lasting drug with a half-life 1.5 times longer than that of Advate. It also reduced the number of administrations to two times per week to enhance patient convenience.

Korea United Pharm’s Forvid (ingredient: tenofovir disoproxil fumarate) has had the reimbursed price of 3,214 won per tablet applied starting on Sunday.

Janssen Korea’s autoimmune disease treatment agent Simponi (ingredient: golimumab) got an expanded indication for active and progressive psoriatic arthritis and severe ankylosing spondylitis, with the drug price lowered from 552,872 won to 522,453 won.